Welcome to the new Outpatient Surgery website! Check out our login FAQs.
Prefilled Syringes Are the Preeminent Option
The benefits of these precise and efficient medications make ditching traditional vials an easy choice for surgical leaders.
Jared Bilski | Interim Editor-in-Chief
Publish Date: November 11, 2022   |  Tags:   Patient Safety Supply Management Financial Management Healthcare IT Waste Management

Superior safety benefits and error-reduction capabilities. Significant time savings. Reduced waste. The benefits of premixed, prelabeled syringes far outweigh the minimal drawbacks, so why are there still facilities that insist on resisting prefilled syringe adoption? 

“While we know that prefilled syringes are safer, I think the hesitation comes from a misunderstanding that it’s not cost effective, that somehow having the user prepare the dose using a vial and syringe is less expensive,” says Susan Paparella, MSN, RN, vice president of the Institute for Safe Medication Practices (ISMP), a non-profit organization dedicated to medication safety education located in Plymouth Meeting, Pa. At least part of this hesitancy comes from a lack of data showing the opposite may in fact be true. But thanks to new research on the cost effectiveness of prefilled medications, the price-tag myth is effectively being challenged. For instance, a recent study in Pain and Therapy found that the use of manufacturer-prepared prefilled ready-to-administer (RTA) syringes can reduce healthcare costs by decreasing errors compared with the traditional vial-and-syringe method. Specifically, the study found that manufacturer-prepared prefilled RTA syringes were associated with an estimated savings of $182.61 per administration and a 94% reduction in errors compared with the traditional IV push vial-and-syringe method. Of course, that’s just one study in an area that has been notoriously unresearched. However, there are a host of benefits to prefilled syringes that have been well documented:

New to Outpatient Surgery Magazine?
Login or subscribe to continue reading this article

DID YOU SEE THIS?